Research Paper Volume 15, Issue 22 pp 12966—12981
Crucial role of hsa-mir-503, hsa-mir-1247, and their validation in prostate cancer
Figure 3. Expression levels of hsa-mir-503/hsa-mir-1247 and their target mRNAs in tumor samples and three PC cell lines. (A–D) Violin diagram of expression differences of DUSP19, FGF2, SLC2A5 and VSTM4 between cancer and para-cancer samples. The horizontal axis was the sample group, the vertical axis was the expression level, and p value was calculated by Wilcoxon method. (E) Expression of hsa-mir-503 in PC-3, LNCaP and 22RV1 cells. (F) Expression of hsa-mir-1247 in PC-3, LNCaP and 22RV1 cells. (G–J) Expression of FGF2, DUSP19, SLC2A5 and VSTM4 in PC-3, LNCaP and 22RV1 cells. (K, L) The expressions of FGF2, DUSP19, SLC2A5 and VSTM4 in 22RV1 cells were detected by WB (*p < 0.05, **p < 0.01, ***p < 0.001 vs. RWPE-1).